GeneDx Chief Financial Officer Kevin Feeley sold 3,729 Class A shares for approximately $227,000 on June 16, 2026, in a transaction tied to the vesting of restricted stock units rather than a discretionary sale. The sale represented 8.54% of Feeley's direct Class A holdings, reducing his position to 39,954 shares, and was executed through a standard sell-to-cover mechanism to satisfy tax withholding obligations. GeneDx reported first-quarter revenue of $102.3 million, up 17% year over year, but lowered its full-year revenue guidance to a top range of $490 million from $555 million. Shares have fallen roughly 27% over the past year, though CEO Katherine Stueland expressed confidence in the company's ability to deliver profitable long-term growth.
GeneDx Holdings Corp.Lowered full-year revenue guidance to top range of $490M from $555M